Literature DB >> 16861118

Prognostic markers under watchful waiting and radical prostatectomy.

Lars Holmberg1, Anna Bill-Axelson, Hans Garmo, Juni Palmgren, Bo Johan Norlén, Hans Olov Adami, Jan Erik Johansson.   

Abstract

A suitable setting to analyze factors that determine prognosis or treatment response in prostate cancer is an unbiased comparison of radical prostatectomy and watchful waiting as in the Scandinavian Prostate Cancer Group Trial number 4. In our previous presentation of 10-year results, we studied Gleason score, serum prostate-specific antigen (PSA) at diagnosis, and age at diagnosis as modifiers of the effect of radical prostatectomy on survival. Because overall prognostic information obtained by these parameters or by tumor stage was not provided in our publication, we now present these data in the two study arms separately.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16861118     DOI: 10.1016/j.hoc.2006.03.007

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  11 in total

Review 1.  The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies.

Authors:  Andreas Pettersson; Travis Gerke; Katja Fall; Yudi Pawitan; Lars Holmberg; Edward L Giovannucci; Philip W Kantoff; Hans-Olov Adami; Jennifer R Rider; Lorelei A Mucci
Journal:  Cancer       Date:  2017-02-02       Impact factor: 6.860

2.  Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures.

Authors:  Nagi Kumar; Theresa Crocker; Tiffany Smith; Julio Pow-Sang; Philippe E Spiess; Shanjayla Connors; Ganna Chornukur; Shohreh Iravani Dickinson; Wenlong Bai; Christopher R Williams; Raoul Salup; Wui Fu
Journal:  J Cancer Sci Ther       Date:  2012-01-10

3.  Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting.

Authors:  Lars Holmberg; Anna Bill-Axelson; Gunnar Steineck; Hans Garmo; Juni Palmgren; Eva Johansson; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

4.  Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy.

Authors:  Nagi B Kumar; Karen Besterman-Dahan; Loveleen Kang; Julio Pow-Sang; Ping Xu; Kathy Allen; Diane Riccardi; Jeffrey P Krischer
Journal:  Clin Med Urol       Date:  2008-04-16

5.  Treating prostate cancer in elderly men: how does aging affect the outcome?

Authors:  Abhay R Shelke; Supriya G Mohile
Journal:  Curr Treat Options Oncol       Date:  2011-09

6.  Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy.

Authors:  Nagi B Kumar; Loveleen Kang; Julio Pow-Sang; Ping Xu; Kathy Allen; Diane Riccardi; Karen Besterman-Dahan; Jeffrey P Krischer
Journal:  J Soc Integr Oncol       Date:  2010

7.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

Review 8.  [Immunohistochemical algorithms in prostate diagnostics: what's new?].

Authors:  G Kristiansen
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

9.  Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.

Authors:  H Ballentine Carter; Anna Kettermann; Christopher Warlick; E Jeffrey Metter; Patricia Landis; Patrick C Walsh; Jonathan I Epstein
Journal:  J Urol       Date:  2007-10-22       Impact factor: 7.450

Review 10.  Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.

Authors:  Ravi Salgia; Mohit Kumar Jolly; Tanya Dorff; Clayton Lau; Keith Weninger; John Orban; Prakash Kulkarni
Journal:  J Clin Med       Date:  2018-06-17       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.